A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas

Trial Profile

A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Chondrosarcoma; Ewing's sarcoma; Osteosarcoma
  • Focus Therapeutic Use
  • Acronyms REGOBONE
  • Most Recent Events

    • 21 Jun 2016 Planned number of patients changed from 108 to 132.
    • 21 Jun 2016 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
    • 21 Jun 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top